An Alzheimer's drug is attracting the spotlight as it enters clinical trials. The drug, called solanezumab, appears to slow the buildup of amyloid beta in the brain and improves cognitive function in patients with mild dementia when given as a monthly shot. But the excitement about the drug is as much a measure of other treatments' failures as it is of its success.
Drug Hopes to Delay Onset of Alzheimer's Symptoms With a Monthly Shot in the Arm
Singularity Hub - 27 Dec 2013 01:24
An Alzheimer's drug is attracting the spotlight as it enters clinical trials. The drug, called solanezumab, appears to slow the buildup of amyloid beta in the brain and improves cognitive function in patients with mild dementia when given as a monthly shot. But the excitement about the drug is as much a measure of other treatments' failures as it is of its success.
Share this Article
Recommended